MaxCyte Signs Akron BioProducts Acquisition Agreement as Stereotaxis Secures Up to $24 Million in Convertible Financing

Biotechnology and medical-technology companies advanced separate capital-allocation plans this week, with MaxCyte signing an agreement to acquire Akron BioProducts and Stereotaxis arranging up to $24 million in convertible financing.

The transactions highlight continued investment in specialized life-sciences platforms, while also underscoring the different ways smaller public companies are using acquisitions and structured financing to expand their operations.

MaxCyte Agrees to Acquire Akron BioProducts

MaxCyte entered into a securities purchase agreement on November 9, 2026, to acquire all outstanding equity interests in Akron BioProducts LLC, according to a filing with the U.S. Securities and Exchange Commission.

The sellers include Ohio TopCo LP and Arcline Capital Partners A LP, affiliates of Arcline Investment Management. The agreement represents the current signed stage of the transaction, although the filing does not disclose a purchase price in the available transaction summary.

Akron BioProducts adds another bioprocessing asset to MaxCyte’s strategic focus. For investors, the transaction could expand MaxCyte’s commercial platform and customer reach, but the eventual financial contribution will depend on closing conditions, integration and the operating performance of the acquired business.

Because the acquisition agreement is not the same as transaction completion, investors will need to monitor subsequent regulatory, financing and closing disclosures. The absence of a disclosed purchase price also limits the ability to assess the deal’s immediate valuation impact.

Stereotaxis Arranges Up to $24 Million in Convertible Notes

Stereotaxis separately entered into a note purchase agreement on November 9, 2026, with accredited investors for convertible promissory notes having an aggregate original principal amount of up to $24 million.

The financing consists of $12 million in initial notes and up to another $12 million in additional notes, subject to the satisfaction or waiver of applicable conditions. The investors include entities affiliated with certain members of the company’s board of directors, according to the SEC filing.

Convertible financing can provide a growth-stage medical-technology company with capital without requiring an immediate traditional equity offering. However, the structure can also create future dilution if the notes convert into common shares, while interest, repayment and conversion terms remain important factors for shareholders to evaluate.

The financing was agreed rather than described as fully deployed capital. Stereotaxis’s next disclosures should clarify how much of the additional tranche is issued, the timing of funding and how the proceeds will support its operations or expansion plans.

Together, the two developments show investors examining both strategic consolidation and flexible financing in the life-sciences sector. MaxCyte’s agreement places the emphasis on acquiring operating capabilities, while Stereotaxis’s note financing provides a potential source of liquidity with future capital-structure implications.